25 may 2021

The message of President Joe Biden to the AACR for the National Cancer Research Month

https://www.aacr.org/about-the-aacr/newsroom/initiatives-and-partnerships/national-cancer-research-month/presidential-message-recognizing-ncrm/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+NCRM+Biden+Letter&utm_term=Biden+Letter+-+Button

8 september 2020

The Europeam Medicines Agency of EU approved durvalumab (anti-PD-L1, Imfinzi) as first line treatment in combination with chemoterapies for small cell lung carcinoma (SCLC).

For complete information, please visit the site:

https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-EU-for-small-cell-lung-cancer.html

28 may 2020

FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC

For complete information on the approval and protocol of treatment, please visit the FDA web site:

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc

20 may 2020

FDA approves atezolizumab (anti-PD-L1) for first-line treatment of metastatic NSCLC with high PD-L1 expression

For full information, visit the FDA website at:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression

31 march 2020

FDA approves Durvalumab, an anti-PD-1 antibody, for the treatment of extensive-stage small-cell lung cancer 

For full information, see the URL:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer

5 march 2020

Cancer Research Institute: new fellowships, deadline 1 april 2020

The CRI Irvington Postdoctoral Fellowship Program provides critical financial support and continued career training to the most promising young scientists in basic and tumor immunology as part of CRI lifesaving work in cancer immunotherapy research

For full information see the URL: https://www.cancerresearch.org/scientists/fellowships-grants/post-doctoral-fellows

17 may 2019

Cancer Research Institute, international reference center for cancer immunotherapy

Cancer Research Institute (CRI) one of the most prestigious international institutions that supports basic and clinical research on tumor immunotherapy, presents its program, informations and most important news on progress in the field that is a major interest of our Association as well.

To know more about the mission and achievements of the CRI, please visit the website

https://www.cancerresearch.org/

19 september 2018

Poliovirus Therapy Extends Survival in Recurrent Glioblastoma

A genetically modified poliovirus therapy shows significantly improved long-term survival for patients with recurrent glioblastoma, according to a study published in The New England Journal of Medicine.

Read the comment at: https://dgnews.docguide.com/poliovirus-therapy-extends-survival-recurrent-glioblastoma?overlay=2&nl_ref=newsletter&pk_campaign=newsletter&nl_eventid=16136

and the article at: http://doi.org/10.1056/NEJMoa1716435

8 may 2018

Cancer Immunotherapy at the Annual Meeting of the AACR 

Over the past few years, cancer immunotherapy has made substantial progress and become an important treatment option for patients with a variety of cancers. At the 2018 annual meeting of the American Association for Cancer Research, held in Chicago, april 14-18, 2018  Immunotherapy dominated the headlines.

For a brief recap of the meeting please visit the website of CRI at:

https://www.cancerresearch.org/blog/april-2018/aacr18-recap-immunotherapy-in-the-spotlight?utm_source=luminate&utm_medium=email&utm_campaign=cancerimmunews&utm_content=may2018

18 april 2018

Checkpoint immunotherapy combination approved for first-line treatment of Advanced Kidney Cancer

Read more in our News section